Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

@article{Usman2018SodiumglucoseC2,
  title={Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis},
  author={Muhammad Shariq Usman and Tariq Jamal Siddiqi and Muhammad Mustafa Memon and Muhammad Shahzeb Khan and Wasiq Faraz Rawasia and Muhammad Talha Ayub and Jayakumar Sreenivasan and Yasmeen Golzar},
  journal={European Journal of Preventive Cardiology},
  year={2018},
  volume={25},
  pages={495 - 502}
}
Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular outcomes have not been well established. We pooled evidence from all available clinical trials to assess the cardiovascular effects of this drug. Design A systematic review and meta-analysis of randomised controlled trials. Methods We queried electronic databases (MEDLINE, Scopus, CENTRAL and clinicaltrials.gov) from their inception to July 2017 for published and unpublished placebo… Expand
Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
TLDR
Results from RCTs confirmed lower risk of death, serious adverse events, hypertension, and edema associated with type 2 diabetes mellitus (T2DM) patients treated with SGLT2 inhibitors when compared with placebo. Expand
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
TLDR
In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. Expand
Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
TLDR
The results support the fact that metformin would not be indispensable to obtain positive cardiovascular effects when new antidiabetic drugs are administered, and show the use of SGLT-2 inhibitors was associated with a reduction in cardiovascular death or hospitalization for heart failure. Expand
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
TLDR
Subgroup analysis showed SGLT-2i reduced the risk of MACE, ACM, HHF, MI, stroke, CVM and HF with a similar benefit regardless of the incidence of CVD, compared to other glucose lowering drugs (oGLD). Expand
Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis.
TLDR
It is suggested that SGLT2i reduce the risk of total stroke in patients with T2DM and impaired renal function and these drugs may offer a protection against hemorrhagic stroke. Expand
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis.
TLDR
SGLT 2 inhibitors are safe, but mildly reduce the HbA1c level, and the clinical significance of SGLT2 inhibitors in the target population was limited. Expand
Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
Cardiovascular (CV) diseases are the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (DM). Therefore, there has been an increasing endorsement from diabeticExpand
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
TLDR
The associations appeared to be consistent across different baseline conditions (DM vs CKD vs HF; atherosclerotic cardiovascular disease [ASCVD] vs no ASCVD) and the SGLT2i used. Expand
Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis
TLDR
A holistic, well-powered assessment of the effect of SGLT2is on the prevention of HF in T2DM patients, as well as in specific subgroups within this population, is provided. Expand
Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis
TLDR
Eertugliflozin results in significant reductions in HbA1c, body weight, SBP and DBP, when compared to control, and subgroup analyses suggest that these effects are not dose-dependent. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
TLDR
Results from RCTs confirmed lower risk of death, serious adverse events, hypertension, and edema associated with type 2 diabetes mellitus (T2DM) patients treated with SGLT2 inhibitors when compared with placebo. Expand
Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
TLDR
Current RCT evidence suggests that 3 common SGLT2 inhibitors are not associated with increased risk of all-cause mortality and CV outcomes when used to treat patients with type 2 diabetes mellitus, and empagliflozin may have a protective effect. Expand
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
TLDR
This meta-analysis evaluated the mid long-term efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in adults with type 2 diabetes mellitus (T2DM) and found that the SGLT 2 inhibitors showed a remarkable reduction of hypoglycemia incidence. Expand
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
TLDR
In patients with type II DM, SGLT-2 inhibitors appeared to reduce both all-cause and cardiovascular mortality, primarily due to reduction in the risk of heart failure, and the benefit was only seen with empagliflozin. Expand
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
TLDR
Net protection of SGLT2 inhibitors against cardiovascular outcomes and death is suggested, driven by findings for empagliflozin (the only S GLT2 inhibitor for which data from a dedicated long-term cardiovascular safety trial have been reported), although results for the other drugs in the class were not clearly different. Expand
Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis
TLDR
Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. Expand
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
TLDR
A significant number of patients would have been potentially eligible for glucose-lowering agents that demonstrated CV benefit in recent clinical trials and a broader and better-targeted use of these medications in evidence-based patient populations are considered. Expand
The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
TLDR
The meta-analysis showed that dapagliflozin as an add-on drug to conventional antidiabetic drugs improved the glycaemic control in T2DM participants without significant body weight gain. Expand
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
The proportion reaching an A1c of <7% was generally similar across therapies (59% for sulfonylurea, 59% for After Metformin, What Comes Next? Empagliflozin). Expand
10-year follow-up of intensive glucose control in type 2 diabetes.
TLDR
Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. Expand
...
1
2
3
...